Literature DB >> 6688529

A new model of osteoarthritis in rabbits. II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemically.

C Colombo, M Butler, L Hickman, M Selwyn, J Chart, B Steinetz.   

Abstract

A battery of drugs with antirheumatic properties was tested for effects on the progress of osteoarthritis induced by a lateral meniscectomy procedure in knee joint cartilage of rabbits. Oral administration of the potent glucocorticoids, paramethasone acetate or triamcinolone, resulted in dramatic inhibition of cartilage degeneration. Significant protection against development of osteoarthritic lesions was also observed in rabbits treated with pirprofen or CGS 5391B but not with 9 other nonsteroidal antiinflammatory drugs. A marked reduction in joint pathology was also observed in rabbits treated with tribenoside (a glucofuranoside derivative) and with tamoxifen (an anti-estrogen). Slightly protective effects of borderline significance were observed with orgotein (a superoxide dismutase), gold sodium thiomalate, and D-penicillamine. Chloroquine and calcitonin were without effect. Therapeutic effectiveness of drugs in this model of osteoarthritis cannot be explained on the basis of their antiinflammatory properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688529     DOI: 10.1002/art.1780260911

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Study of the effect of a glycosaminoglycan-peptide complex on the degradative enzyme activities in human osteoarthritic cartilage.

Authors:  E Vignon; A Martin; P Mathieu; T Conrozier; P Louisot; M Richard
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

2.  Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage.

Authors:  J P Pelletier; J Martel-Pelletier
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  In vitro effects of tiaprofenic acid, sodium salicylate and hydrocortisone on human osteoarthritic cartilage degradation and synovial collagenase synthesis.

Authors:  J P Pelletier; J Martel-Pelletier
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Osteoarthritis 1991. Current drug treatment regimens.

Authors:  A al Arfag; P Davis
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

5.  Estrogenic impregnation alters pain expression: analysis through functional neuropeptidomics in a surgical rat model of osteoarthritis.

Authors:  Sokhna Keita-Alassane; Colombe Otis; Emilie Bouet; Martin Guillot; Marilyn Frezier; Aliénor Delsart; Maxim Moreau; Agathe Bédard; Isabelle Gaumond; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Francis Beaudry; Bertrand Lussier; Roger Lecomte; Serge Marchand; Eric Troncy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-23       Impact factor: 3.000

Review 6.  Pirprofen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; R Beresford
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

7.  Spontaneous osteo-arthritis of the knee-joint in C57BL mice receiving chronic oral treatment with NSAID's or prednisone.

Authors:  A Pataki; H P Graf; E Witzemann
Journal:  Agents Actions       Date:  1990-03

8.  Physiological levels of hydrocortisone maintain an optimal chondrocyte extracellular matrix metabolism.

Authors:  J Wang; D Elewaut; I Hoffman; E M Veys; G Verbruggen
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

9.  Inhibition of relaxin-induced pubic symphyseal "relaxation" in guinea pigs by glycosaminoglycan polysulfates and pentosan polysulfate.

Authors:  B G Steinetz; G Lust
Journal:  Agents Actions       Date:  1994-08

Review 10.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.